Journal of Comparative Effectiveness Research This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Visualizing the target estimand in comparative effectiveness studies with multiple treatments
Conclusion: Visualization tools may help to clarify the target population in comparative effectiveness studies and resolve ambiguity about the interpretation of estimated treatment effects.PMID:38261336 | PMC:PMC10842272 | DOI:10.57264/cer-2023-0089 (Source: Journal of Comparative Effectiveness Research)
Source: Journal of Comparative Effectiveness Research - January 23, 2024 Category: General Medicine Authors: Gabrielle Simoneau Marian Mitroiu Thomas Pa Debray Wei Wei Stan Rw Wijn Joana Caldas Magalh ães Justin Bohn Changyu Shen Fabio Pellegrini Carl de Moor Source Type: research

Estimating utility values for non-alcoholic steatohepatitis health states: a discrete choice experiment
Conclusion: Three methods were used to estimate utilities for NASH, each one showed sensitivity to advancing fibrosis, including in the early stages, which is often considered asymptomatic.PMID:38226909 | PMC:PMC10842270 | DOI:10.57264/cer-2023-0033 (Source: Journal of Comparative Effectiveness Research)
Source: Journal of Comparative Effectiveness Research - January 16, 2024 Category: General Medicine Authors: Daniel Aggio Katy Gallop Villum Wittrup-Jensen Soulmaz Fazeli Farsani Andrew J Lloyd Source Type: research

Navigating the unknown: how to best 'reflect' standard of care in indications without a dedicated treatment pathway in health technology assessment submissions
J Comp Eff Res. 2024 Feb;13(2):e230145. doi: 10.57264/cer-2023-0145. Epub 2024 Jan 16.ABSTRACTThere is an urgent need for expedited approval and access for new health technologies targeting rare and very rare diseases, some of which are associated with high unmet treatment needs. Once a new technology achieves regulatory approval, the technology needs to be assessed by health technology assessment (HTA) bodies to inform coverage and reimbursement decisions. This assessment quantitatively examines the clinical effectiveness, safety and/or economic impact of the new technology relative to standard of care (SoC) in a specific...
Source: Journal of Comparative Effectiveness Research - January 16, 2024 Category: General Medicine Authors: Grammati Sarri Maria Rizzo Sheela Upadhyaya Victoria Federico Paly Luis Hernandez Source Type: research

Corrigendum
J Comp Eff Res. 2024 Jan 16:e240003c1. doi: 10.57264/cer-2024-0003. Online ahead of print.NO ABSTRACTPMID:38226925 | DOI:10.57264/cer-2024-0003 (Source: Journal of Comparative Effectiveness Research)
Source: Journal of Comparative Effectiveness Research - January 16, 2024 Category: General Medicine Source Type: research

Corrigendum
J Comp Eff Res. 2024 Feb;13(2):e240003c1. doi: 10.57264/cer-2024-0003c1. Epub 2024 Jan 16.NO ABSTRACTPMID:38226946 | DOI:10.57264/cer-2024-0003c1 (Source: Journal of Comparative Effectiveness Research)
Source: Journal of Comparative Effectiveness Research - January 16, 2024 Category: General Medicine Source Type: research

Smart connected insulin dose monitoring technologies versus standard of care: a Canadian cost-effectiveness analysis
Conclusion: For adults with T1DM in Canada, a connected insulin pen device is likely to be a cost-effective treatment option associated with greater clinical benefits and lower costs relative to a standard re-usable or disposable pen.PMID:38205726 | DOI:10.57264/cer-2023-0124 (Source: Journal of Comparative Effectiveness Research)
Source: Journal of Comparative Effectiveness Research - January 11, 2024 Category: General Medicine Authors: Katalina Chan K åre Hansen Sergey Muratov Shoghag Khoudigian Mark Lamotte Source Type: research

Radiofrequency ablation using the ThermoCool SmartTouch Catheter guided by ablation index versus antiarrhythmic drugs in atrial fibrillation treatment in China: a cost-consequence analysis
Conclusion: Radiofrequency catheter ablation using SmartTouch catheter guided by Ablation Index was superior to AADs as the first-line AF treatment in Chinese setting with better clinical outcomes and at lower costs over a 10-year time horizon.PMID:38205729 | PMC:PMC10842291 | DOI:10.57264/cer-2023-0035 (Source: Journal of Comparative Effectiveness Research)
Source: Journal of Comparative Effectiveness Research - January 11, 2024 Category: General Medicine Authors: Biqi Zhang Jie Han Dongchen Zhou Jiajia Jiang Jiawei Zhong Yunlong Lu Chenyu Zuo Xingwei Lu Jianwei Xuan Aohan Zu Yuxian He Xingang Sun Lu Chen Liangrong Zheng Source Type: research

Quantitative bias analysis for external control arms using real-world data in clinical trials: a primer for clinical researchers
J Comp Eff Res. 2024 Jan 11:e230147. doi: 10.57264/cer-2023-0147. Online ahead of print.ABSTRACTDevelopment of medicines in rare oncologic patient populations are growing, but well-powered randomized controlled trials are typically extremely challenging or unethical to conduct in such settings. External control arms using real-world data are increasingly used to supplement clinical trial evidence where no or little control arm data exists. The construction of an external control arm should always aim to match the population, treatment settings and outcome measurements of the corresponding treatment arm. Yet, external real-...
Source: Journal of Comparative Effectiveness Research - January 11, 2024 Category: General Medicine Authors: Kristian Thorlund Stephen Duffield Sanjay Popat Sreeram Ramagopalan Alind Gupta Grace Hsu Paul Arora Vivek Subbiah Source Type: research

R WE ready for reimbursement? A round up of developments in real-world evidence relating to health technology assessment: part 14
J Comp Eff Res. 2024 Jan;13(1):e230189. doi: 10.57264/cer-2023-0189. Epub 2024 Jan 4.ABSTRACTIn this latest update we highlight: a publication from the US FDA regarding the definitions of real-world data (RWD) and real-world evidence (RWE); a publication from academic researchers on a demonstration project for target trial emulation; a publication from the National Institute of Health and Care Excellence (NICE) on the 1 year anniversary of their RWE framework; and a publication from NICE and Flatiron Health on the utility of US RWD for initial UK health technology assessment decision making.PMID:38179957 | PMC:PMC10842288 ...
Source: Journal of Comparative Effectiveness Research - January 5, 2024 Category: General Medicine Authors: Benjamin D Bray Sreeram V Ramagopalan Source Type: research

R WE ready for reimbursement? A round up of developments in real-world evidence relating to health technology assessment: part 14
J Comp Eff Res. 2024 Jan;13(1):e230189. doi: 10.57264/cer-2023-0189. Epub 2024 Jan 4.ABSTRACTIn this latest update we highlight: a publication from the US FDA regarding the definitions of real-world data (RWD) and real-world evidence (RWE); a publication from academic researchers on a demonstration project for target trial emulation; a publication from the National Institute of Health and Care Excellence (NICE) on the 1 year anniversary of their RWE framework; and a publication from NICE and Flatiron Health on the utility of US RWD for initial UK health technology assessment decision making.PMID:38179957 | DOI:10.57264/cer...
Source: Journal of Comparative Effectiveness Research - January 5, 2024 Category: General Medicine Authors: Benjamin D Bray Sreeram V Ramagopalan Source Type: research

Justifying the source of external comparators in single-arm oncology health technology submissions: a review of NICE and PBAC assessments
Conclusion: Although HTA bodies such as NICE and PBAC encourage that EC source justification should be provided in submissions, this review found that this is not typically implemented in practice. Guidance is needed to establish best practices as to how EC selection should be documented in HTA submissions.PMID:38174576 | DOI:10.57264/cer-2023-0140 (Source: Journal of Comparative Effectiveness Research)
Source: Journal of Comparative Effectiveness Research - January 4, 2024 Category: General Medicine Authors: Katherine Appiah Maria Rizzo Grammati Sarri Luis Hernandez Source Type: research

Comparative effectiveness of erenumab versus rimegepant for migraine prevention using matching-adjusted indirect comparison
Conclusion: In the present study, we found that erenumab had a more favorable efficacy profile than rimegepant in reducing MMDs at month 1 and month 3 for migraine prevention. These results may help with decision-making in clinical practice and can be further validated in future clinical trials or real-world studies.PMID:38174577 | DOI:10.57264/cer-2023-0122 (Source: Journal of Comparative Effectiveness Research)
Source: Journal of Comparative Effectiveness Research - January 4, 2024 Category: General Medicine Authors: Ronan Mahon Santosh Tiwari Mirja Koch Matias Ferraris Keith A Betts Yan Wang Sophie Gao Pascal Proot Source Type: research

Justifying the source of external comparators in single-arm oncology health technology submissions: a review of NICE and PBAC assessments
Conclusion: Although HTA bodies such as NICE and PBAC encourage that EC source justification should be provided in submissions, this review found that this is not typically implemented in practice. Guidance is needed to establish best practices as to how EC selection should be documented in HTA submissions.PMID:38174576 | DOI:10.57264/cer-2023-0140 (Source: Journal of Comparative Effectiveness Research)
Source: Journal of Comparative Effectiveness Research - January 4, 2024 Category: General Medicine Authors: Katherine Appiah Maria Rizzo Grammati Sarri Luis Hernandez Source Type: research